LONDON, Sept. 17, 2002 (PRIMEZONE) -- Iain Buchanan discusses the breadth of Vertex's (Nasdaq:VRTX) development pipeline and the earnings potential of tie ups with EliLilly, Novartis and Aventis.
Ian F Smith tackles issues around the development of the next generation of HIV treatments and the expansion, through acquisition, into the area of Kinase inhibitors for the treatment of Psoriasis and inflammatory diseases.
Interviews with AFFYMETRIX, GENZYME GENERAL and SEPRACOR also available on Cantos today.
This interview is available in video, audio and transcript.
It's free to view. All you need to do is register at http://www.cantos.com
Cantos.com is an online financial website where top management of companies address the critical issues facing their businesses.
If you would like to contact us, please email enquiries@cantos.com.